)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
EXACT Therapeutics
EXACT Therapeutics (EXTX) investor relations material
EXACT Therapeutics H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary3 Sep, 2026
Executive summary
Advanced the Phase 2 ENACT trial for PS101 in pancreatic cancer, completing two positive safety reviews and enabling unrestricted enrolment at the higher 60 μl/kg dose.
Early clinical data showed substantial reductions in tumour marker CA 19-9 and encouraging radiological responses, with one patient achieving complete surgical resection.
Raised NOK 59.4 million through warrant exercises, strengthening the financial position.
Approved delisting from Euronext Growth Oslo, with last trading day set for 9 October 2026.
Financial highlights
Net loss for H1 2026 was NOK -38.0 million, improved from NOK -49.2 million in H1 2025.
Total operating expenses decreased to NOK 38.0 million from NOK 45.8 million year-over-year.
Payroll and related expenses were NOK 11.7 million, down from NOK 16.1 million in H1 2025.
Free cash and cash equivalents at 30 June 2026 were NOK 49.1 million, up from NOK 24.4 million at year-end 2025.
Total assets increased to NOK 85 million from NOK 67.4 million at year-end 2025.
Outlook and guidance
Focus remains on patient enrolment and execution of the ENACT Phase 2 trial at 60 μl/kg.
Interim efficacy analysis expected around end of 2026; final analysis planned for H1 2027.
Exploring future opportunities for PS101 in combination with RAS-targeted therapies.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from EXACT Therapeutics
- Delisting aims to unlock VC funding and reduce costs as clinical progress accelerates.EXTX
Status update - ENACT Phase 2 trial advanced, R&D costs rose, and liquidity secured via warrant exercise.EXTXH2 2025
- Strong early clinical results and secured funding support expansion in oncology and beyond.EXTXInvestor update
- Ultrasound-activated therapy achieved >10x tumor reduction and advances to Phase 2 in pancreatic cancer.EXTXISTU 2024 presentation
- ACT delivers >10x tumor shrinkage in liver metastases and advances to Phase 2 pancreatic cancer trials.EXTXCMR Symposium 2024 presentation
- $13M raised, including $7M from a medtech leader, to fund phase II trial and expand ACT platform.EXTXStatus update
- PS101 delivers promising early results in pancreatic cancer, with strong clinical and financial momentum.EXTXCompany presentation
- ACT technology shows strong clinical promise in oncology, with Phase 2 trials underway.EXTXDNB Carnegie Nordic Healthcare Conference Presentation
- ENACT Phase 2 trial launched, ACTIVATE Phase 1 results strong, cash burn rises with clinical progress.EXTXH1 2025
Next EXACT Therapeutics earnings date
H2 20268 Apr, 2027
EXACT Therapeutics
Next EXACT Therapeutics earnings date
H2 20268 Apr, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage